Skip to content
Principal report of the Medical Research Council's AML 9 study. MRC Leukaemia in Adults Working PartyHematopoietic stem cell transplantation across major genetic barriers: tolerance induction by megadose CD34 cells and other veto cellsAcute leukemia during pregnancy: the Toronto Leukemia Study Group experience with long‐term follow‐up of children exposed in utero to chemotherapeutic agentsA randomized placebo‐controlled phase III study of granulocyte–macrophage colony‐stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490)A phase 3 study of three induction regimens and of priming with GM‐CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology GroupA new morphological classification system for acute promyelocytic leukemia distinguishes cases with underlying A modified AIDA protocol with anthracycline‐based consolidation results in high antileukemic‐positive acute efficacy and reduced toxicity in newly diagnosed PML/RAR promyelocytic leukemiaRisk‐adapted treatment of acute promyelocytic leukemia with all‐The tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemiaReduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factorScreening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AMLNucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotypeUnrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experienceEfficacy and safety of gemtuzumab ozogamicin in patients with CD33‐positive acute myeloid leukemia in first relapseGranulocyte‐macrophage colony‐stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia.
Platelet support may be required (Central nervous system relapse is generally followed by marrow relapse if not already present. Et je n’exagère même pas !
Aujourd’hui je viens vous présenter la Rolls de l’escarpin, la grande prêtresse du talon, j’ai nommé Patricia Blanchet.
Ses chaussures ne sont pas juste jolies, elles sont tout ce que vous avez toujours rêvé pour vos petons. Patients with a high presenting white cell count (>10 × 10Approximately 10% of relapses involve an extramedullary site (most commonly CNS, particularly in patients initially presenting with elevated white cell count) and this should be considered in the assessment and management of relapsed disease (reviewed in As an alternative to ATO, ATRA combined with chemotherapy or GO may induce a second CR, but ATRA alone should not be used for treatment of relapse due to high rates of secondary resistance (reviewed in The optimum management of relapsed APL remains to be established; however, the key aim is to induce molecular remission, as this is essential to achieve cure (grade B; evidence level IIb).
(C) COPYRIGHT 2018 - ALL RIGHTS RESERVED Nous utilisons des cookies pour vous garantir la meilleure expérience sur notre site. In the UK MRC AML 9 study, patients were randomised to receive DAT in a 1 + 5 or a standard 3 + 10 regimen: patients receiving DAT 1 + 5 were less likely to achieve CR, and required more time in hospital and more blood product support (The role of MDR modulators is unclear although MDR expression is more prevalent.